CCCC vs. EDIT, TRML, TSHA, REPL, VYGR, ALEC, EXAI, OCGN, FATE, and LXEO
Should you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Editas Medicine (EDIT), Tourmaline Bio (TRML), Taysha Gene Therapies (TSHA), Replimune Group (REPL), Voyager Therapeutics (VYGR), Alector (ALEC), Exscientia (EXAI), Ocugen (OCGN), Fate Therapeutics (FATE), and Lexeo Therapeutics (LXEO). These companies are all part of the "biological products, except diagnostic" industry.
C4 Therapeutics (NASDAQ:CCCC) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.
C4 Therapeutics has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.
Editas Medicine received 277 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 54.04% of users gave Editas Medicine an outperform vote while only 37.50% of users gave C4 Therapeutics an outperform vote.
78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 8.0% of C4 Therapeutics shares are held by insiders. Comparatively, 1.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
C4 Therapeutics has a beta of 3.18, suggesting that its stock price is 218% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.
Editas Medicine has a net margin of -196.12% compared to C4 Therapeutics' net margin of -638.34%. Editas Medicine's return on equity of -42.95% beat C4 Therapeutics' return on equity.
C4 Therapeutics currently has a consensus price target of $10.25, indicating a potential upside of 48.55%. Editas Medicine has a consensus price target of $15.00, indicating a potential upside of 174.73%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than C4 Therapeutics.
In the previous week, Editas Medicine had 5 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Editas Medicine and 0 mentions for C4 Therapeutics. Editas Medicine's average media sentiment score of 0.60 beat C4 Therapeutics' score of 0.00 indicating that Editas Medicine is being referred to more favorably in the news media.
Summary
Editas Medicine beats C4 Therapeutics on 12 of the 18 factors compared between the two stocks.
Get C4 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
C4 Therapeutics Competitors List
Related Companies and Tools
